⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30402790 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL20295378 | 0.98 | MAPT (0.40) | — | |
| Hydrochloric Acid SCHEMBL3890783 | 0.81 | MAPT (0.41) | — | |
| SCHEMBL1422106 | 0.79 | — | — | |
| SCHEMBL16646215 | 0.77 | — | — | |
| SCHEMBL13034200 | 0.77 | — | — | |
| SCHEMBL30168270 | 0.77 | — | — | |
| SCHEMBL14747547 | 0.77 | — | — | |
| SCHEMBL131994 | 0.77 | — | — | |
| SCHEMBL15264888 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11851425-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridines | H. LUNDBECK A/S (DK) | 2023-12-26 | — | — | US | disclosed |
| US-11634416-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines | H. LUNDBECK A/S (DK) | 2023-04-25 | — | — | US | disclosed |
| US-11491140-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2022-11-08 | — | — | US | disclosed |
| EP-3723808-B1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES | H LUNDBECK AS (DK) | 2021-10-20 | — | — | EP | disclosed |
| EP-3723807-B1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES | H LUNDBECK AS (DK) | 2021-10-20 | — | — | EP | disclosed |
| US-11026924-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2021-06-08 | — | — | US | disclosed |
| US-11026923-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2021-06-08 | — | — | US | disclosed |
| US-20210023056-A1 | 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2021-01-28 | — | — | US | disclosed |
| US-20210015794-A1 | 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2021-01-21 | — | — | US | disclosed |
| US-20200385381-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES | H. LUNDBECK A/S (DK) | 2020-12-10 | — | — | US | disclosed |
| WO-2009042694-A1 | (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING | COMENTIS, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009015369-A2 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| WO-2009015369-A2 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| US-7342013-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-03-11 | — | — | US | disclosed |
| US-7314874-B2 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide;modified amidine elements of high potency in vitro, excellent pharmacological and pharmaceutical properties in vivo | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-7285565-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-7285565-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | MILLENNIUM PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | MILLENNIUM PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20040116399-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |